Advertisement

Topics

Chiesi Farmaceutici S.p.A. Company Profile

21:52 EST 14th December 2018 | BioPortfolio

Chiesi Pharmaceuticals, which started up in 1935 as a small family company is today an international company in the pharmaceutical sector and operates in all 5 continents with 24 direct branches, 3 manufacturing plants and 4 research centres situated in Parma (Italy), Paris, Rockville (Maryland - USA) and Chippenham (UK). The Company's history of continual development is founded on concepts which constitute the basis for its management: strategic innovation, internationalization and ability to plan taking care in the creation of socially compatible economic values.

 

Thanks to the process of internationalization and strategic alliances with international pharmaceutical groups, Chiesi Group drugs and technologies are today distributed in over 65 countries. The Group employs over 3,800 people, approximately 320 of whom are researchers who work in the four Research and Development laboratories, and approximately 600 of whom are employed in the manufacturing sites in Italy, France and Brazil.

Our Mission

 

  • Our aim is to be recognised as a research-focused international Group, able to develop and commercialise innovative pharmaceutical solutions to improve the quality of human life.
  • We want to maintain a high quality entrepreneurial team characterised by self confidence and a collaborative spirit.
  • Our goal is to combine commitment to results with integrity, operating in a socially and environmentally responsible manner

Location

Via Palermo, 26/A
Parma
IT-43122
Italy

Contact

Phone: +39 0521 279
Fax: +39 0521 774468


News Articles [27 Associated News Articles listed on BioPortfolio]

Protalix BioTherapeutics Expands Partnership with Chiesi Farmaceutici to Include Exclusive U.S. Rights for the Development and Commercialization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease

Protalix to receive $25 million upfront, an additional up to $20 million in development costs and an additional up to $760 million in potential regulatory and commercial milestone payments for the U....

Chiesi Gains U.S. Rights to Protalix' Phase III Fabry Disease Candidate PRX-102

Protalix BioTherapeutics said today it has granted Chiesi Farmaceutici exclusive U.S. rights to develop and commercialize the Phase III Fabry disease treatment PRX-102 (pegunigalsidase alfa), in an ex...

New patent expiration for Chiesi Usa drug KENGREAL

Annual Drug Patent Expirations for KENGREAL Kengreal is a drug marketed by Chiesi Usa Inc and is included in one NDA. It is available from two suppliers. There are ten… The post New patent expiratio...

Chiesi's limbal stem cell deficiency drug gets FDA orphan status

Limbal stem cell deficiency drug candidate GPLSCD01 from Chiesi USA received orphan drug status from the FDA. -More- 

Chiesi Farmaceutici SpA Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 13112018] Prices from USD $250

SummaryChiesi Farmaceutici SpA Chiesi researches, develops, produces and commercializes novel medicines with focus on respiratory, neonatology, rare disease and special care therapeutic areas. The com...

Chiesi Farmaceutici SpA Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 16042018] Prices from USD $250

SummaryChiesi Farmaceutici SpA Chiesi researches, develops, produces and commercializes novel medicines with focus on respiratory, neonatology, rare disease and special care therapeutic areas. The com...

Rounds Report: Protalix And Chiesi Expanded The PRX-102 Partnership To Cover U.S. Territories

Holoclar® - The first stem-cell therapy approved for medical use in Europe

Dr Andreas Chiesi, CEO, Holostem Terapie Avanzate S.r.l

Drugs and Medications [1 Associated Drugs and Medications listed on BioPortfolio]

Curosurf [Cornerstone Therapeutics Inc.]

CUROSURF (poractant alfa)Intratracheal Suspension

PubMed Articles [3 Associated PubMed Articles listed on BioPortfolio]

Phospholipid components of the synthetic pulmonary surfactant CHF5633 probed by fluorescence spectroscopy.

CHF5633 (Chiesi Farmaceutici, Italy) is a synthetic pulmonary surfactant currently under clinical development for the treatment of Respiratory Distress Syndrome in premature infants. The product is co...

Quenching of tryptophan fluorescence in a highly scattering solution: Insights on protein localization in a lung surfactant formulation.

CHF5633 (Chiesi Farmaceutici, Italy) is a synthetic surfactant developed for respiratory distress syndrome replacement therapy in pre-term newborn infants. CHF5633 contains two phospholipids (dipalmit...

Triticum vulgare extract exerts an anti-inflammatory action in two in vitro models of inflammation in microglial cells.

Triticum vulgare has been extensively used in traditional medicine thanks to its properties of accelerating tissue repair. The specific extract of Triticum vulgare manufactured by Farmaceutici Damor (...

Clinical Trials [4 Associated Clinical Trials listed on BioPortfolio]

Efficacy and Tolerability of Beclomethasone Plus Salbutamol in HFA pMDI Fixed Combination vs Beclomethasone Plus Salbutamol in CFC pMDI Fixed Combination in a 12-week Treatment Period of Adult Patients With Uncontrolled Asthma

The purpose of this trial is to verify if the test treatment BDP 250 mcg/salbutamol 100 mcg HFA pMDI fixed combination is non-inferior to BDP 250 mcg/salbutamol 100 mcg pMDI fixed combina...

Evaluation of the Filler Performance on the Nasolabial Folds of Aliaxin® EV With and Without Lidocaine 0.3%

Evaluation of the filler performance on the nasolabial folds of Aliaxin® EV with and without lidocaine 0.3%: comparison within subjects (half face method)

Evaluation of the Re-volumizing Performance of Aliaxin (New Trademark)

Aim of the study is to evaluate the re-volumizing performance and the duration effect of the product Aliaxin (new trademark) in women aged 40-65 years with midface volume defects due to ag...

Early Viscosupplementation After Partial Meniscectomy: a Randomized Controlled Trial

The rational of intra-articular viscosupplementation is based on both the biological and mechanical properties of HA, which exerts positive effects on the modulation of the entire joint en...

Companies [8 Associated Companies listed on BioPortfolio]

Chiesi Farmaceutici S.p.A.

Chiesi Pharmaceuticals, which started up in 1935 as a small family company is today an international company in the pharmaceutical sector and operates in all 5 continents with 24 direct branches, 3 ...

Chiesi Group

The Company, founded in Parma in 1935, is today an international reality in the pharmaceutical market. With global operations consisting of 21 direct affiliates, 3 manufacturing sites, and 3 research ...

Fidia Farmaceutici

Fidia Farmaceutici is part of Fidia Pharma Group, an Italian multinational company, with R&D, manufacturing and sales capabilities, and an extensive product portfolio mainly based...

Fidia Farmaceutici S.p.A.

Fidia Farmaceutici is part of Fidia Pharma Group, an Italian multinational company, with R&D, manufacturing and sales capabilities, and an extensive product portfolio mainly based...

Mediolanum farmaceutici S.p.A

Nil

More Information about "Chiesi Farmaceutici S.p.A." on BioPortfolio

We have published hundreds of Chiesi Farmaceutici S.p.A. news stories on BioPortfolio along with dozens of Chiesi Farmaceutici S.p.A. Clinical Trials and PubMed Articles about Chiesi Farmaceutici S.p.A. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Chiesi Farmaceutici S.p.A. Companies in our database. You can also find out about relevant Chiesi Farmaceutici S.p.A. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record